ReviewIndian journal of endocrinology and metabolism
Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement.
Review in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04198948 (Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis.Journal of diabetes research · 2022Pooled it
- Effect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients.Indian journal of pharmacology · 2024Trial
- Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.Advances in therapy · 2022Trial
- Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.Diabetes, obesity & metabolism · 2016 · on this mapTrial
- Article
- From Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care.Current diabetes reports · 2025Review
- Trends in global glucose lowering medication consumption: Insights from pharmaceutical sales data (2010-2021).PLOS global public health · 2025Article
- Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional, Real-World Study.Journal of the ASEAN Federation of Endocrine Societies · 2024Article
- Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus.Archives of medical science : AMS · 2024Article
- The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Diabetes among Muslims during Ramadan: A narrative review.World journal of clinical cases · 2023Review
- Therapeutic Potential of Quercetin in the Management of Type-2 Diabetes Mellitus.Life (Basel, Switzerland) · 2022Review
- Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations.Nature reviews. Endocrinology · 2022Review
- Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines.Clinical medicine insights. Endocrinology and diabetes · 2022Review
- Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma.Journal of experimental & clinical cancer research : CR · 2021Article
- Review
- Hepatotoxicity Induced by Fluvastatin: A Reversible Acute Cholestatic Liver Injury.The American journal of case reports · 2021Article
- The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Single Nucleotide Polymorphisms Associated with Metformin and Sulphonylureas' Glycaemic Response among South African Adults with Type 2 Diabetes Mellitus.Journal of personalized medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 11 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since their introduction in clinical practice in the 1950's, Sulfonylureas (SUs) have remained the main-stay of pharmacotherapy in the management of type 2 diabetes. Despite their well-established benefits, their place in therapy is inappropriately being overshadowed by newer therapies. Many of the clinical issues associated with the use of SUs are agent-specific, and do not pertain to the class as such. Modern SUs (glimepiride, gliclazide MR) are backed by a large body of evidence, experience, and most importantly, outcome data, which supports their role in managing patients with diabetes. Person-centred care, i.e., careful choice of SU, appropriate dosage, timing of administration, and adequate patient counseling, will ensure that deserving patients are not deprived of the advantages of this well-established class of anti-diabetic agents. Considering their efficacy, safety, pleiotropic benefits, and low cost of therapy, SUs should be considered as recommended therapy for the treatment of diabetes in South Asia. This initiative by SAFES aims to encourage rational, safe and smart prescription of SUs, and includes appropriate medication counseling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.